Review of novel biotherapeutics for diabetic wound healing, identifying thymosin β4 alongside growth factors (EGF, FGF, PDGF), immunomodulators, and advanced delivery platforms as major therapeutic targets. Discusses TB4's role in addressing the impaired angiogenesis, chronic inflammation, and defective cell migration that characterize diabetic wounds. Positions TB4 within the current landscape of biomolecular and cellular approaches to chronic wound management.
Singh, Suraj Kumar; Dwivedi, Shradha Devi; Yadav, Krishna; Shah, Kamal; Chauhan, Nagendra Singh; Pradhan, Madhulika; Singh, Manju Rawat; Singh, Deependra